TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05132790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316 at a dose 20mg/kg q3w
Description: Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390 at a dose of 150mg orally, daily
Description: SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: radiation therapy for breast cance before surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: radiation therapy for breast cance before surgery.
Study: NCT06613035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor: 60 mg/day from days -9 to -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Selinexor: 60 mg/day from days -9 to -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Busulfan
Description: 3.2 mg/kg on days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Busulfan
Description: 3.2 mg/kg on days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² on days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² on days
Study: NCT06668103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK043 in combination with Firmonertinib
Description: Two potential dose levels ：400 mg twice daily （BID） and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD).~Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy.~Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.~After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study.
Study: NCT05690763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XP-endo Finisher to use irrigation activation
Description: XPF : The canals were flushed with 2.5 mL 2.5% NaOCl for 30 s and activated by a XPF instrument that was placed in the canal to 1 mm short of the WL and powered by the motor at 800 rpm (1 N-cm torque) for 30 s according to the manufacturer's instructions. Then the canals were rinsed with 2.5 mL of 2.5% NaOCl, followed by activation of the substance with the XPF instrument for 30 seconds, the same way as above. A new XP-endo Finisher file was used for each canal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EndoActivator to use irrigation activation
Description: The root canals were irrigated with 2.5 mL of 2.5% NaOCl for 30 s, followed by sonic activation of this solution with EndoActivator red tip size #25/0.04, inserted into the root canal 1 mm short of the WL, at 10,000 cpm/min. for 30 seconds. The EA polymer tip moved vertically from apical to coronal part of the canal during activation.
Study: NCT05194943

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
Study: NCT06385925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN1611
Description: TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN1611
Description: TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study: NCT06417034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Software
Description: The software is interfaced with a modified version of Frets on Fire (FOF)-an open source computer game similar to Guitar Hero.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Game Software
Description: The software is interfaced with a modified version of Frets on Fire (FOF)-an open source computer game similar to Guitar Hero.
Study: NCT06095531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetranite for Cranial Flap Fixation (TN-CFF)
Description: Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
Study: NCT06485583

Intervention type: OTHER
Group type: OTHER
Intervention: Constraint-induced movement therapy
Description: is a rehabilitation technique used to improve motor function in people who have had a stroke or other neurological conditions. CIMT restricts the use of the unaffected limb, typically with a mitt or sling, to encourage the use of the affected limb.

Intervention type: OTHER
Group type: OTHER
Intervention: Neurodevelopmental Treatment
Description: Therapy, is a rehabilitation approach used to address movement and motor control deficits in people with neurological illnesses such as stroke, cerebral palsy, or traumatic brain injury.
Study: NCT05382039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: High frequency sensory transcutaneous electrical nerve stimulation
Study: NCT06060483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR\>70%, TBR\<4%, TAR\<25%, and HbA1c\<7.0%. After the treatment reaches the standard, CGM is worn every six months.
Study: NCT06736912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-114199 10mg or placebo
Description: IN-114199 10mg or placebo (1 Tablet, QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-114199 10mg or placebo
Description: IN-114199 10mg or placebo (1 Tablet, QD)
Study: NCT06547567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: In addition to receiving the same health education intervention as the control group, the children and adolescents in the intervention group will undergo a group-based motivational interviewing intervention. This will be conducted by a professional team that has been trained and is qualified in motivational interviewing. The intervention will embody the spirit of motivational interviewing and the stages of group motivation development, primarily including: introductory tasks, exploratory tasks, expansion tasks, and action planning tasks.
Study: NCT06456606

Intervention type: PROCEDURE
Intervention: before prone position
Description: It was evaluated with transesophageal echocardiography

Intervention type: PROCEDURE
Intervention: the first hour of prone position
Description: It was evaluated with transesophageal echocardiography

Intervention type: PROCEDURE
Intervention: the first hour of returning to the supine position
Description: It was evaluated with transesophageal echocardiography
Study: NCT06736912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-114199 20mg or placebo
Description: IN-114199 10mg or placebo (2 Tablets, QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-114199 20mg or placebo
Description: IN-114199 10mg or placebo (2 Tablets, QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-114199 40mg or placebo
Description: IN-114199 10mg or placebo (4 Tablets, QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-114199 5mg or placebo
Description: IN-114199 2.5mg or placebo (2 Tablets, QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-114199 5mg or placebo
Description: IN-114199 2.5mg or placebo (2 Tablets, QD)
Study: NCT06737211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peripheral Parenteral Nutrition
Description: 2000 mL of peripheral parenteral nutrition with electrolytes (20 mL 7.45% KCl, 10 mL 20% MgSO4 and 20 mL 8.7% Na3PO4) will be administered via a peripheral venous catheter with a rhythm of 80cc/h from the time they will leave the operation room and will be transferred to the ward or the critical care unit (CCU) until the 5th postoperative day
Study: NCT05194943

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

Intervention type: PROCEDURE
Intervention: revisional bariatric surgical procedures
Description: Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
Study: NCT05546320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: Anticoagulation or anti-platelet or migraine medication therapy will be provided for different groups.
Study: NCT05282836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen Oxygen Generator with Nebulizer
Description: Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
Study: NCT05546320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 25 Mg Oral Tablet
Description: Metoprolol 25mg will be provided for the participants twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75mg will be provided for the participant once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Description: Rivaroxaban 20mg will be provided for the participant once a day.
Study: NCT04927923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hope-focused motivational interview
Description: The eight-week hope-focused motivational interview will be applied to each individual individually during dialysis treatment. Within the scope of the study, a hope tree will be created for each individual together with the patients to be used in the evaluation process of the interview sessions. Through the hope tree, it is aimed for the individual to set goals, to discover the obstacles and solutions in achieving these goals.
Study: NCT05131347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor intervention
Description: Children in the motor intervention group will receive motor skills training based on motor learning theory. Movement activities include playing on trampoline and tilt board, walking on knees, toes and heels, creeping and crawling under different obstacles, jumping forward and backward, driving scooter board, playing balance devices, hopping, and visual motor coordinated movement. These activities are designed from easy to complex.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive intervention
Description: Children in the cognitive intervention group will receive cognitive training. The activities consist of 12 exercises with progressive cognitive demands at 10 levels to improve cognitive functions such as attention, cognitive flexibility, inhibitory control, and working memory.
Study: NCT04965337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42
Description: ASC42 tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42
Description: ASC42 tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally
Study: NCT06452290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain 18F-FDG PET-CT
Description: PET scanner, Philips VEREOS PET/CT scanner. Three Philips VEREOS digital PET/CT scanners are installed in the nuclear medicine department.
Study: NCT05624736

Intervention type: DIAGNOSTIC_TEST
Intervention: multi-parametric magnetic resonance imaging scan
Description: Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.

Intervention type: DIAGNOSTIC_TEST
Intervention: multi-parametric magnetic resonance imaging scan
Description: Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.

Intervention type: DIAGNOSTIC_TEST
Intervention: multi-parametric magnetic resonance imaging scan
Description: Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology examination
Description: The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology examination
Description: The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology examination
Description: The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
Study: NCT05616598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
Description: Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
Study: NCT05781165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality
Description: Step-by-step 3D models displayed with augmented reality guiding the self-test procedures
Study: NCT06442696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education: Healthy Choices Program
Description: Six session for students and school personel
Study: NCT05890937

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral and practical exam
Description: Oral and practical exam that performed at the end of the semester
Study: NCT05332678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-005 - Once Weekly
Description: Please see Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-005 - Twice Weekly
Description: Please see Arm description.
Study: NCT05317676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palmitoylethanolamide
Description: 2-month supply of PEA will be given upon discharge. 300mg will be taken twice a day in conjunction with discharge medications (opioid and NSAIDs).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-month supply of placebo will be given upon discharge. Placebo will taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
Study: NCT06476938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene PilotLX
Description: eHealth decision making tool regarding tumor genomic profiling
Study: NCT05599386

Intervention type: DIAGNOSTIC_TEST
Intervention: Preoperative test
Description: Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
Study: NCT05558436

Intervention type: DIAGNOSTIC_TEST
Intervention: Genome-wide methylation profiling
Description: Detection for colorectal tumor-specific ctDNA methylation biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: Genome-wide methylation profiling
Description: Detection for colorectal tumor-specific ctDNA methylation biomarkers
Study: NCT04456244

Intervention type: OTHER
Intervention: Evaluation of the static posture
Description: Photographing from the back, front and side with ADIBAS posturography in standing position

Intervention type: OTHER
Intervention: Evaluation of the static posture
Description: Photographing from the back, front and side with ADIBAS posturography in standing position
Study: NCT06076408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAGS with Pilates
Description: Patients will Receive Sustained Natural Apophyseal glides and Pilates Technique. Pilates Exercises focusses on five main areas (breath control, pelvic lumbar region, chest, shoulder positioning, head and neck positioning) a special session was organized for each patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAGS
Description: Patients will Receive Sustained Natural Apophyseal glides
Study: NCT05953831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDR132L
Description: CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to CDR132L
Study: NCT04915131

Intervention type: DEVICE
Group type: OTHER
Intervention: Bloomlife MFM-Pro
Description: Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes.
Study: NCT04722536

Intervention type: PROCEDURE
Intervention: Cervico-isthmic cerclage
Description: There is no intervention in this study. It's an observational retrospective study, before/after.
Study: NCT05762952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Once daily oral dapagliflozin 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules formulated by pharmacy to be indistinguishable from active drug
Study: NCT05069298

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Silibinin A
Description: The compound will be administered following a 300 mg / 3 day schedule, before each main meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silibinin A
Description: The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
Study: NCT05566392

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
Study: NCT04952701

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control lenses
Description: Control Multifocal lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control lenses
Description: Control Multifocal lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test lenses
Description: Test Multifocal lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lenses
Description: Test Multifocal lenses
Study: NCT06311643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum back massage in study group
Description: Effleurage massage from shoulders toward lower back
Study: NCT05297344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct pulp capping
Description: direct pulp capping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy
Description: pulpotomy
Study: NCT04919070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect for Caregivers
Description: The intervention being studied is a single session guided behavioral intervention to improve social connectedness in caregivers of individuals with ADRD. The intervention, Connect for Caregivers, provides psychoeducation on the importance of social connectedness for health and well-being, includes a card-sort process to identify and prioritize barriers to connectedness, and provides personalized resources and strategies for caregivers to use to increase their social connectedness.